Integra LifeSciences Acquires ACell, Inc.

Convatec Group Acquires Triad Life Sciences

January 28, 2022

Medical Devices

Convatec Group Plc has signed a definitive agreement to acquire Triad Life Sciences Inc, a Memphis-based developer and manufacturer of porcine placenta‑derived extracellular matrix products for advanced wound care. The deal, expected to close in Q1 2022 subject to regulatory approvals, values Triad at an initial $125 million with up to $275 million additional contingent/earnout payments tied to milestones and performance.

Integra LifeSciences Acquires Acclarent, Inc.

April 1, 2024

Medical Devices

Integra LifeSciences Holdings Corporation has completed its acquisition of Acclarent, Inc., a maker of ear, nose and throat (ENT) surgical devices. The transaction expands Integra’s product portfolio into the ENT device segment, adding approximately $1 billion to the company’s total addressable market and providing scale through Acclarent’s commercial and R&D capabilities.

Solventum Acquires Acera Surgical

December 23, 2025

Medical Devices

Solventum (NYSE: SOLV) has completed the acquisition of Acera Surgical, a privately held bioscience company that develops synthetic tissue matrices for regenerative wound care, for $725 million upfront plus up to $125 million in contingent payments. The deal expands Solventum's MedSurg and advanced wound care portfolio with Acera's synthetic electrospun matrix technology; Acera is expected to generate about $90 million in sales in 2025.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Discovery Life Sciences Acquires AllCells

July 12, 2022

Biotechnology

Discovery Life Sciences has acquired AllCells to create an integrated, end-to-end provider of clinical-grade and RUO primary cell products and analytic services for the cell and gene therapy (CGT) continuum. The combined business — operating as AllCells, a Discovery Life Sciences Company and led by AllCells CEO Danny Zheng — aims to expand GMP-compliant starting materials, donor programs and multi‑omic characterization to accelerate CGT discovery through commercialization.

Integra LifeSciences Acquires Surgical Innovation Associates (SIA)

December 1, 2022

Medical Devices

Integra LifeSciences agreed to acquire Surgical Innovation Associates (SIA), the developer of DuraSorb, a resorbable synthetic matrix for plastic and reconstructive (including implant-based breast) surgery. Integra will pay $50 million at closing with up to $90 million in contingent consideration to support its expansion into breast reconstruction and strengthen its soft tissue reconstruction portfolio.